MediPharm Labs (MLZ) Stock Overview
Operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MLZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
MediPharm Labs Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.036 |
| 52 Week High | CA$0.07 |
| 52 Week Low | CA$0.03 |
| Beta | 0.75 |
| 1 Month Change | -14.55% |
| 3 Month Change | -14.95% |
| 1 Year Change | -11.22% |
| 3 Year Change | -31.71% |
| 5 Year Change | -90.47% |
| Change since IPO | -97.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| MLZ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.6% | 1.7% | -1.2% |
| 1Y | -11.2% | -3.4% | 9.8% |
Return vs Industry: MLZ underperformed the German Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: MLZ underperformed the German Market which returned 8.7% over the past year.
Price Volatility
| MLZ volatility | |
|---|---|
| MLZ Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: MLZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MLZ's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 161 | David Pidduck | www.medipharmlabs.com |
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products.
MediPharm Labs Corp. Fundamentals Summary
| MLZ fundamental statistics | |
|---|---|
| Market cap | €16.82m |
| Earnings (TTM) | -€4.93m |
| Revenue (TTM) | €28.35m |
Is MLZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLZ income statement (TTM) | |
|---|---|
| Revenue | CA$46.10m |
| Cost of Revenue | CA$32.14m |
| Gross Profit | CA$13.96m |
| Other Expenses | CA$21.99m |
| Earnings | -CA$8.02m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 30.28% |
| Net Profit Margin | -17.41% |
| Debt/Equity Ratio | 0.9% |
How did MLZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 20:36 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MediPharm Labs Corp. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Tamy Chen | BMO Capital Markets Equity Research |
| Kimberly Thompson-Hedlin | Canaccord Genuity |